Actinium Pharmaceuticals Inc. (ATNM)
Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
📈 **POSITIVE** • Low confidence analysis (46%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (78%) **Content type:** Clinical